Schexnayder L W, Hirschowitz J, Sautter F J, Garver D L
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75216, USA.
Am J Psychiatry. 1995 Oct;152(10):1511-3. doi: 10.1176/ajp.152.10.1511.
This study sought to characterize a subset of patients with DSM-III schizophrenia or schizophreniform disorder who respond to lithium.
Sixty-six psychotic patients were given a systematic therapeutic trial of lithium alone. Differences in demographic characteristics, symptoms, and family history of psychotic disorders between the responders and nonresponders to lithium were explored.
Responders and nonresponders did not differ significantly in age, duration of illness, length of current episode, distribution of RDC and DSM-III diagnoses, or number of positive symptoms. However, the responders to lithium (N = 10) exhibited a paucity of negative symptoms and an absence of familial schizophrenic spectrum disorders.
These preliminary results suggest the possibility of pretreatment identification of psychotic patients for whom neuroleptic medication could be avoided by therapeutic intervention with lithium alone.
本研究旨在对一组对锂盐有反应的DSM-III精神分裂症或精神分裂症样障碍患者进行特征描述。
66名精神病患者接受了单独使用锂盐的系统治疗试验。探讨了锂盐反应者与非反应者在人口统计学特征、症状以及精神病性障碍家族史方面的差异。
反应者与非反应者在年龄、病程、当前发作时长、RDC和DSM-III诊断分布或阳性症状数量上无显著差异。然而,锂盐反应者(N = 10)表现出较少的阴性症状且无家族性精神分裂症谱系障碍。
这些初步结果表明,有可能在治疗前识别出仅通过锂盐治疗干预即可避免使用抗精神病药物的精神病患者。